Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone978-600-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$563.82 million
Profitability
Miscellaneous
Employees1,169
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Monday, August, 5th. The medical instruments supplier reported $0.02 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.01. The medical instruments supplier earned $177.10 million during the quarter, compared to analyst estimates of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 7.85%. The firm's revenue for the quarter was up 42.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.03) EPS. View Insulet's Earnings History.
When is Insulet's next earnings date?
What guidance has Insulet issued on next quarter's earnings?
Insulet issued an update on its third quarter 2019 earnings guidance on Monday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $174-181 million, compared to the consensus revenue estimate of $172.7 million.
What price target have analysts set for PODD?
14 equities research analysts have issued 1 year price targets for Insulet's stock. Their predictions range from $100.00 to $160.00. On average, they expect Insulet's stock price to reach $132.6923 in the next twelve months. This suggests that the stock has a possible downside of 14.8%. View Analyst Price Targets for Insulet.
What is the consensus analysts' recommendation for Insulet?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.
Has Insulet been receiving favorable news coverage?
News headlines about PODD stock have been trending somewhat negative on Sunday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Insulet earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Insulet.
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), Tandem Diabetes Care (TNDM), NuVasive (NUVA) and ICU Medical (ICUI).
What other stocks do shareholders of Insulet own?
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
- Mr. Charles Alpuche, Exec. VP & COO (Age 59)
- Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
- Mr. Patrick J. Sullivan, Consultant (Age 67)
- Mr. Michael L. Levitz, Advisor (Age 45)
Who are Insulet's major shareholders?
Insulet's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.77%), Primecap Management Co. CA (7.56%), William Blair Investment Management LLC (3.87%), JPMorgan Chase & Co. (2.71%), Waddell & Reed Financial Inc. (1.39%) and Marshall Wace North America L.P. (1.22%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.
Which major investors are selling Insulet stock?
PODD stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Primecap Management Co. CA, Point72 Asset Management L.P., UBS Asset Management Americas Inc., KAMES CAPITAL plc, Balyasny Asset Management LLC, Russell Investments Group Ltd. and Rockefeller Capital Management L.P.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.
Which major investors are buying Insulet stock?
PODD stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Nuveen Asset Management LLC, Rock Springs Capital Management LP, William Blair Investment Management LLC, Kornitzer Capital Management Inc. KS, Renaissance Technologies LLC, C WorldWide Group Holding A S and Jennison Associates LLC. View Insider Buying and Selling for Insulet.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $155.80.
How big of a company is Insulet?
Insulet has a market capitalization of $9.39 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.
What is Insulet's official website?
How can I contact Insulet?
Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (NASDAQ PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
